^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    H002

    i
    Other names: H002, RC-01, H-002
    Company:
    Hongyun Biotech
    Drug class:
    EGFR inhibitor
    Related drugs:
    1year
    Phase I/IIa Study of H002 in NSCLC With Active EGFR Mutation (clinicaltrials.gov)
    P1/2, N=76, Recruiting, RedCloud Bio | Not yet recruiting --> Recruiting | Initiation date: Aug 2022 --> Dec 2022
    Enrollment open • Trial initiation date • Metastases
    |
    EGFR mutation • EGFR C797S
    |
    H002
    over1year
    Phase I/IIa Study of H002 in NSCLC With Active EGFR Mutation (clinicaltrials.gov)
    P1/2, N=76, Not yet recruiting, RedCloud Bio
    New P1/2 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR C797S
    |
    H002